Mark Herbert Joins METiS Pharmaceuticals as Chief Business Officer to Drive Growth

Mark Herbert Joins METiS Pharmaceuticals as Chief Business Officer

On March 3, 2025, METiS Pharmaceuticals, a pioneering AI-driven biotechnology firm focused on innovative drug delivery technologies, announced the appointment of Mark Herbert as their new Chief Business Officer (CBO), effective January 22, 2025. This strategic hire marks a significant step forward for METiS as it seeks to expand its global presence and reinforce its commitment to delivering cutting-edge therapies.

Mark Herbert brings with him over 20 years of distinguished experience within the biotechnology and pharmaceutical sectors. His extensive background includes a successful tenure as President of Arcturus Therapeutics, where he was instrumental in establishing strategic partnerships with renowned companies such as Takeda Pharmaceutical and CureVac. Through these collaborations, Herbert helped secure a remarkable partnership value exceeding $2 billion, demonstrating his adeptness in fostering valuable business connections and driving commercialization.

Prior to joining METiS, Herbert held vital positions as Vice President of Business Development at Varda Space Industries and Chief Business Officer at Scientist.com. His experience on the boards of multiple biotech companies further highlights his leadership acumen. With such a strong foundation in business development, Herbert is well-positioned to lead METiS into its next phase of growth and innovation.

Dr. Chris Lai, co-founder and CEO of METiS Pharmaceuticals, expressed enthusiasm regarding Herbert’s appointment. He noted, "Mark is a highly experienced executive with a proven track record in driving business development and commercialization in the biotech space. His leadership will be crucial in strengthening our partnerships and unlocking new growth opportunities, especially as we approach this pivotal phase for our company."

Echoing Lai’s sentiments, Dr. Hongmin Chen, co-founder and Chief Research and Development Officer (CRDO), acknowledged Herbert’s deep industry knowledge and global perspective as invaluable assets. Chen stated, "His leadership will enhance our business development efforts and foster partnerships that will enable our transformative drug delivery technologies to reach patients globally."

Mark Herbert himself expressed excitement upon joining the METiS team: "It’s a tremendous honor to join METiS Pharmaceuticals. I look forward to closely collaborating with our talented team to advance our innovative nucleic acid and drug delivery technologies. METiS is at the forefront of using artificial intelligence to revolutionize drug delivery, and I am thrilled to be part of this exciting journey."

METiS Pharmaceuticals has made substantial progress in the area of AI-driven lipid nanoparticle (LNP) delivery systems, achieving significant advancements in targeted nano delivery for various organs including the liver, lungs, spleen, muscles, and the central nervous system. Their innovations have led to a reported efficacy rate that exceeds industry standards by as much as 20 times for conditions such as liver cancer and lung tumors.

Additionally, the company has curated strategic collaborations with over 20 leading global pharmaceutical and biotech firms, enhancing its capabilities in drug delivery technology.

With Mark Herbert now at the helm of global business development, METiS Pharmaceuticals is poised to embark on a new and exciting chapter. The company remains resolute in its mission to provide transformative therapies through its innovative delivery technologies, making a significant impact on the lives of patients worldwide.

About METiS Pharmaceuticals

Founded in 2020, METiS Pharmaceuticals stands at the intersection of technology and healthcare, utilizing cutting-edge AI, machine learning, and quantitative modeling to redefine drug delivery and development. The company is committed to pioneering programmable nucleic acid therapeutics and next-generation RNA delivery systems, addressing significant unmet medical needs and striving to deliver groundbreaking treatments to patients around the globe.